EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
THIS EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of June 5, 2023 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “ Company”), and Rakhi Kumar, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AND SALE AGREEMENTRevenue Interest Purchase and Sale Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
This First Amendment to Revenue Interest Purchase and Sale Agreement (this “Amendment”) is made as of May 24, 2024, by and among DERMAVANT SCIENCES GMBH, a limited liability company organized under the laws of Switzerland (“Dermavant”), DERMAVANT SCIENCES, LTD., an exempted company organized under the laws of Bermuda, solely for purposes of Section 5.21 and Article VIII of the RIPSA (“Parent” and, together with Dermavant, the “Dermavant Parties”), XYQ LUXCO S.À R.L. (“XYQ Luxco”), NovaQuest Co-Investment Fund XVII, L.P. (“NovaQuest”), MAM Tapir Lender, LLC (“Marathon” and, with XYQ Luxco and NovaQuest, the “Purchasers”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as collateral agent on behalf of the Purchasers (the “Collateral Agent”).
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
This CREDIT AGREEMENT dated as of May 14, 2021 by and among DERMAVANT SCIENCES LTD., an exempted company incorporated under the laws of Bermuda (the “Parent” or the “Bermuda Borrower”), DERMAVANT HOLDINGS LIMITED, a private limited company incorporated under the laws of England and Wales (the “English Borrower”), DERMAVANT SCIENCES IRL LIMITED, a private company limited by shares incorporated under the laws of Ireland with a registered office address at Rocktwist House, Block 1, Western Business Park, Shannon, Co. Clare, Ireland (the “Irish Borrower”) DERMAVANT SCIENCES GMBH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and organized under the laws of Switzerland (the “Swiss Borrower”), EACH SUBSIDIARY OF THE PARENT LISTED AS A GUARANTOR ON THE SIGNATURE PAGES HEREOF (the “Initial Guarantors”), EACH OTHER SUBSIDIARY OF THE PARENT OTHERWISE PARTY FROM TIME TO TIME HERETO, as a borrower or a guarantor, XYQ LUXCO S.À R.L. (the “Lender”), and U.S. BANK T
SECOND AMENDMENT TO FUNDING AGREEMENTFunding Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
This Second Amendment to Funding Agreement (this “Amendment”) is made as of May 24, 2024, by and among DERMAVANT SCIENCES GMBH, a company organized under the laws of Switzerland (“Dermavant”), DERMAVANT SCIENCES LTD., an exempted company organized under the laws of Bermuda, solely with respect to Section 8.7 and ARTICLE XI of the Funding Agreement (as defined below) (“Dermavant Parent” and, with Dermavant, the “Dermavant Parties”), and NOVAQUEST CO-INVESTMENT FUND VIII, L.P., a limited partnership organized under the laws of Delaware (“NovaQuest”).
